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Though tailored for Canada, these guidelines from an internationally respected centre 
offer valuable guidance to clinicians in Britain and elsewhere on a form of the main 
alternative to methadone for the maintenance treatment of addiction to heroin and allied 
drugs, one whose greater safety counterbalances greater cost.
The following account broadly reproduces the document's summary with the addition 
(because discontinuation is not dealt with in the summary) of the section from the main 
text on tapering stable patients.
These Canadian guidelines provide clinical recommendations for the initiation, 
maintenance and discontinuation of buprenorphine/naloxone maintenance treatment for 
opioid dependence in Ontario. The focus is on the combination product (marketed as 
Suboxone) because this is the only sublingual buprenorphine product available in Canada 
for maintenance treatment. The addition of naloxone is intended to deter injection 
because if taken in this way the naloxone is active and could precipitate withdrawal in 
people dependent on drugs like heroin and methadone. The buprenorphine is the active 
ingredient which by substituting for the opiate-type drugs the patient is dependent on is 
intended to safeguard them from harm related to injecting and the use of illegally 
acquired drugs, stabilise their lives, and to bring them in to a setting where their 
addiction can be treated. 
The guidelines were developed by a multidisciplinary committee, including specialists in 
addiction medicine, family medicine and pharmacy, who had available to them the results 
of a systematic review of the literature which formed the evidence base for the 
guidelines. Recommendations were assigned levels of evidence depending on the 
methodological rigour of the supporting studies, and grades which reflect the level of 
evidence plus clinical expertise.
The background to the guidelines is that opioid dependence is an increasing clinical and 
public health problem in Canada, yet only an estimated 25% of people dependent on 
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opioids are enrolled in a methadone programme. Methadone uptake is limited by issues 
of access, especially in non-urban areas, as well as patient disinterest. Due in part to its 
demonstrated effectiveness and safety in the primary care setting, buprenorphine/
naloxone has the potential to improve access to evidence-based treatment for opioid 
dependence.
Selecting buprenorphine maintenance treatment
• Buprenorphine/naloxone is an effective medication for the maintenance treatment of 
opioid dependence. It improves outcomes compared to detoxification and, with the 
exception of retention in treatment, appears to be of equal efficacy compared to 
methadone.
Clinical assessment
• Contraindications to initiation of buprenorphine/naloxone are: 
– allergy to buprenorphine/naloxone; 
– pregnancy (for buprenorphine/naloxone combination product specifically); 
– severe liver dysfunction; 
– acute severe respiratory distress; 
– paralytic ileus; 
– decreased level of consciousness; 
– inability to provide informed consent. 
• Exercise caution if baseline liver enzymes are elevated above 3–5 times the upper limit 
of normal. 
• The clinical assessment will include the establishment of the diagnosis of opioid 
dependence, an estimation of degree of the patient's physical dependence on opioids and 
their level of psychosocial functioning, an appreciation of other concurrent medical and 
psychiatric diagnoses and an understanding of the patient's treatment goals. Urine drug 
testing and a small but important selection of other laboratory tests are also essential 
components of the assessment.
Preparation
• Ensure a clinical assessment has resulted in a diagnosis of opioid dependence, a urine 
drug test has been interpreted and is positive for opioids, and that there has been a 
consideration of the contraindications to initiating buprenorphine/naloxone. 
• Ensure the patient has provided informed consent to buprenorphine maintenance 
treatment, is aware of the possible long-term nature of this treatment and has been 
made aware of other treatment options. A written consent and treatment agreement may 
be useful. 
• Ensure that there are no concurrent substance use disorders, psychiatric illnesses or 
medical disorders that should be stabilised prior to induction of buprenorphine/naloxone. 
• Inform the patient how long to remain abstinent from opioids to maximise the 
likelihood of beginning their induction in satisfactory withdrawal to minimise the 
likelihood of precipitated withdrawal during the induction. 
• Ensure the patient has no plans to drive a vehicle or operate heavy machinery during 
the early induction period.
Induction
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• Patient presents in moderate opioid withdrawal to the physician's office as early in the 
day as possible. 
• After an assessment to establish the severity of opioid withdrawal, the physician 
prescribes an initial induction dose of 2–4mg of buprenorphine/naloxone (though it could 
be as high as 6mg), to be administered sublingually. 
• The ingestion of the dose is observed by a pharmacist or other health care professional 
to ensure the tablet has dissolved completely. 
• Consideration is given to reassessing the patient one hour after the dose to assess for 
precipitated withdrawal. 
• If necessary, the patient is reassessed after approximately three hours to assess 
effectiveness of the initial dose and consider prescribing an additional observed dose (to 
a maximum of 8mg total on the first day). If after this re-assessment the prescriber is 
unsure about the need for another buprenorphine/naloxone dose, the prescriber may also 
consider prescribing one or two 2mg tablets of buprenorphine/naloxone for the patient to 
take home on that first induction day in case withdrawal symptoms emerge later in the 
evening (not exceeding 8mg total on the first day). 
• The prescriber either asks to see the patient the next day or writes a prescription for 
observed once-daily dosing of buprenorphine/naloxone for the next one to two days for 
the total amount taken by the patient on day one. At the follow-up appointment the 
patient is assessed for the effectiveness of the dose and any side effects. The patient is 
made aware they can present for reassessment earlier than the suggested day if they are 
feeling the dose is very inadequate or they are having side effects from the dose. 
• At each follow-up visit, the buprenorphine/naloxone dose is titrated, generally by 2–
4mg at a time, until an optimal maintenance dose is reached. An optimal dose is one 
where, among other things, the patient is free of opioid withdrawal symptoms for the full 
24-hour dosing interval without experiencing intoxication or sedation from the medication.
Maintenance
• Once at the maintenance dose and more clinically stable, patient visits become 
gradually less frequent. Even a highly stable patient should be assessed at least every 12 
weeks. Visits will again be more frequent during periods of instability. 
• At follow-up visits, patient clinical stability is ascertained using the clinical assessment 
and urine drug testing. 
• Areas to cover at follow-up visits include: adequacy of the dose and side effects, 
substance use, psychiatric symptoms, employment, social relationships, and participation 
in counselling/mutual aid groups. 
• Once the patient is at a stable maintenance dose, consideration can be given to 
alternate-day dosing (ie, double the dose on Monday, Wednesday and Friday and a single 
dose on Sunday). 
• Patients should not receive a dose of buprenorphine/naloxone if they appear intoxicated 
or sedated upon presenting for their dose. 
• The prescriber should have a structured approach to missed doses. 
• The prescriber should have a structured approach to deciding about initiating and 
increasing the number of take-home doses once the patient achieves clinical stability.
Take-home doses
• Prescribing of take-home doses of buprenorphine/naloxone is a therapeutic intervention 
with benefits and risks. 
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• Take-home doses should not be initiated until the patient exhibits features of clinical 
stability. Exercise caution if patient has recently been suicidal, is injecting, is cognitively 
impaired or has unstable housing. 
• Generally, tighter boundaries should be loosened as the patient displays increased 
clinical stability rather than tightening initially looser boundaries in response to instability. 
• There should be a gradual increase in the number of weekly take-home doses up to a 
suggested maximum of one to two weeks of consecutive take-home doses dispensed 
between observed doses. 
• Health Canada states that all doses are to be observed, with the exception of weekends 
and holidays, for at least the first two months on buprenorphine/naloxone. If the 
prescriber feels that a patient is eligible for additional regular take-home doses earlier 
than two months, this should be justified in the clinical record and the patient needs to 
have explicitly consented to this 'against label' prescription. 
• When about to receive their first take-home dose(s), all patients should be made aware 
of the risks to themselves, their family and the public. 
• Take-home doses should be reduced or eliminated in response to a loss of clinical 
stability. If high levels of take-home doses are eliminated all at once and if misuse or 
diversion of the take-home doses is suspected, the prescriber should strongly consider 
reducing the buprenorphine/naloxone dose by 25–50%. This would reduce the likelihood 
of opioid toxicity once the patient starts ingesting their buprenorphine/naloxone doses on 
a daily basis.
Adverse events and safety
• Buprenorphine's partial mu agonist pharmacodynamic properties suggest that there is 
less risk of overdose and short-term mortality compared to full mu agonists such as 
methadone. Population-level studies appear to consistently and robustly support that 
hypothesis. 
• There is evidence that this medication can be prescribed as safely and effectively by 
appropriately trained or experienced practitioners in a primary care clinic as it can be in a 
clinic which specialises in prescribing opiate-type drugs in the treatment of addiction. 
• Risk of harm with buprenorphine does still exist, including the risk of injecting the drug, 
so practitioners must be systematic and thorough in their approach to diagnosing opioid 
dependence, determining eligibility for buprenorphine/naloxone and inducting and 
maintaining patients on buprenorphine/naloxone maintenance therapy. 
Tapering stable patients
• Buprenorphine/naloxone maintenance treatment is generally considered a long-term 
treatment with no predetermined end point. That said, there will be patients for whom a 
taper off of buprenorphine/naloxone maintenance has been agreed upon by the patient 
and prescriber. 
• Ideally, patients taper off of buprenorphine/naloxone maintenance while drug-free, 
functioning well and with ongoing psychosocial support. In some circumstances patients 
may choose to taper off under less than ideal circumstances (eg, ongoing drug use or 
ongoing social instability). 
• Regardless of the clinical circumstances, buprenorphine/naloxone should be tapered 
gradually, perhaps by 2mg per week initially, and the taper rate adjusted based on the 
patient's experience of the taper. 
• Throughout the taper patients should be monitored carefully for withdrawal, cravings, 
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and lapses to drug use. If clinical stability is lost during the taper, re-titration of the 
buprenorphine/naloxone dose should be recommended to the patient. 
 
 Though tailored for Canada, these guidelines from an internationally 
respected centre offer valuable guidance to clinicians in Britain and elsewhere. Uniquely 
they focus on the buprenorphine/naloxone product rather than buprenorphine, but the 
recommendations are usually appropriate to both. Realistically they admit that the anti-
injection properties of the combination product – its main claim to being preferred to 
alternatives – are not 100%. Non-dependent opioid abusers, they say, still get a 'buzz' 
from injecting the product as do some patients maintained on buprenorphine/naloxone, 
and there is substantial evidence that the combination product finds an illicit market. 
Such considerations are important, because they mean that if supervised consumption is 
thought necessary at least initially to prevent buprenorphine being diverted on to the 
illicit market, the same is true of the combination product. This undermines its 
anticipated advantages as a medication potentially prescribed widely from GP's surgeries 
in regimens which reduce supervision costs and the restrictions supervision places on 
patients' working and family lives. However, buprenorphine with or without naloxone 
lends itself to being taken every other day, meaning that even if supervision is thought 
necessary, the attendance burden is halved compared to methadone.
An international review and UK guidance have contrasted the virtues of methadone 
versus buprenorphine. Like the featured guidance, these found little in the research to 
indentify who would do best on one drug or the other. The Findings analysis tentatively 
offered the indications that buprenorphine possibly helps depressed patients more than 
those not suffering depression, while patients dependent on large doses of opiates may 
find it inadequate because there is a ceiling beyond which higher doses do not augment 
opiate-type effects. Patients who value the 'wrapped in cotton wool' feeling typical of 
heroin may prefer methadone, while those who value a clearer mind might prefer 
buprenorphine.
Britain's National Institute for Health and Clinical Excellence suggests that when for an 
individual the medications are equally appropriate, methadone might take precedence 
because it costs less and on average extends the benefits of being in treatment. With the 
emphasis in Britain shifting from retention to treatment exit and concern over recently 
increased numbers of methadone-involved overdose deaths, buprenorphine with or 
without naloxone could find a greater profile, especially if the cost savings of alternate 
day dosing, less need to supervise consumption, and primary care rather than clinic-
based treatment, are fully realised to counter the greater cost of the drug and the 
greater time required for each supervised consumption.
For other guidelines offering advice on buprenorphine maintenance run this search on the Findings site.
This draft entry is currently subject to consultation and correction by the study authors and other experts. 
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